Previous studies have confidently reported that the poor outcome in younger AML patients is owning to dual NUP98/NSD1 positivity and FLT3/ITD positivity, with a high overlap for those two genetic lesions. This evidence concerns the gene NSD1 and acute myeloid leukemia.